GlaxoSmithKline Sees Red at Design of Rival’s Purple Asthma Inhaler

GlaxoSmithKline (GSK) said Rowex Ltd is preparing to sell a product similar in its packaging to the “Seretide” inhaler and that this infringed its trademark.

Seretide is the fourth-highest-selling pharmaceutical product in the world, with more than $62bn (€58bn) in global sales, including Ireland.

The UK-based Glaxo Group, along with GSK (Ireland) Ltd, trading as Allen and Hanburys, is to apply next month for an injunction preventing Rowex, a member of the Rowa group, from launching an inhaler called “AirFluSal”.

Help employers find you! Check out all the jobs and post your resume.

Source: BioSpace